Brought to you by 
Teva buys Novopharm's generic business for $258mm
17 Feb 2000
Executive Summary
Teva (Israeli generics company) is entering the Canadian market through the purchase of the generics business of Novopharm from Dan Family Holdings for $257.88mm in Teva stock. The acquisition does not include Novopharm's OTC business--which will be sold--or Novopharm Biotech, which is publicly traded.
Deal Industry
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Teva buys Novopharm's generic business for $258mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice